Phase I trial evaluating the safety and immunogenicity of candidate TB vaccine MVA85A, delivered by aerosol to healthy M.tb-infected adults

Phase I trial evaluating the safety and immunogenicity of candidate TB vaccine MVA85A, delivered by aerosol to healthy M.tb-infected adults

The immunogenicity of the candidate tuberculosis (TB) vaccine MVA85A may be enhanced by aerosol delivery. Intradermal administration was shown to be safe in adults with latent TB infection (LTBI), but data are lacking for aerosol-delivered candidate TB vaccines in this population. We carried out a P...

Volledige beschrijving

Bibliografische gegevens
Hoofdauteurs:	Riste, M, Marshall, JL, Satti, I, Harris, SA, Wilkie, M, Lopez Ramon, R, Wright, D, Wittenberg, RE, Vermaak, S, Powell Doherty, R, Lawrie, A, Conlon, CP, Cosgrove, C, Gleeson, F, Lipman, M, Moss, P, Perrin, F, Dedicoat, M, Bettinson, H, McShane, H
Formaat:	Journal article
Taal:	English
Gepubliceerd in:	MDPI 2021

Gelijkaardige items

Phase I Trial Evaluating the Safety and Immunogenicity of Candidate TB Vaccine MVA85A, Delivered by Aerosol to Healthy <em>M.tb</em>-Infected Adults
door: Michael Riste, et al.
Gepubliceerd in: (2021-04-01)

Evaluating aerosol administration of a candidate TB vaccine MVA85A
door: Thomas, Z, et al.
Gepubliceerd in: (2014)

The candidate TB vaccine, MVA85A, induces highly durable Th1 responses.
door: Tameris, M, et al.
Gepubliceerd in: (2014)

The candidate TB vaccine, MVA85A, induces highly durable Th1 responses
door: Tameris, M, et al.
Gepubliceerd in: (2014)

DEVELOPING A NEW TB VACCINE: BOOSTING BCG WITH MVA85A
door: Mcshane, H
Gepubliceerd in: (2008)

Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: A phase I randomised controlled trial
door: Manjaly Thomas, Z, et al.
Gepubliceerd in: (2019)

A review of the tolerability of the candidate TB vaccine, MVA85A compared with BCG and Yellow Fever vaccines, and correlation between MVA85A vaccine reactogenicity and cellular immunogenicity
door: Rowland, R, et al.
Gepubliceerd in: (2012)

The candidate TB vaccine, MVA85A, induces highly durable Th1 responses.
door: Michele Tameris, et al.
Gepubliceerd in: (2014-01-01)

Comparison of the safety and immunogenicity of a candidate TB vaccine, MVA85A, given by the intramuscular or intradermal route in BCG-vaccinated adults
door: Harris, S, et al.
Gepubliceerd in: (2011)

Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery.
door: Meyer, J, et al.
Gepubliceerd in: (2013)

Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery
door: Meyer, J, et al.
Gepubliceerd in: (2013)

Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: A phase I randomised controlled trial.
door: Zita-Rose Manjaly Thomas, et al.
Gepubliceerd in: (2019-04-01)

The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: An open-label trial.
door: Anne Wajja, et al.
Gepubliceerd in: (2017-05-01)

The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: An open-label trial
door: Wajja, A, et al.
Gepubliceerd in: (2017)

Phase I/II clinical trial of MVA85A in individuals with latent tuberculosis: The first subunit TB vaccine in clinical trial
door: Sander, C, et al.
Gepubliceerd in: (2005)

A Phase I study evaluating the safety and immunogenicity of MVA85A, a candidate TB vaccine, in HIV-infected adults
door: Minassian, A, et al.
Gepubliceerd in: (2011)

Evaluation of a human BCG challenge model to assess antimycobacterial immunity induced by BCG and a candidate TB vaccine, MVA85A, alone and in combination
door: Harris, S, et al.
Gepubliceerd in: (2013)

A new TB vaccine, MVA85A, induces durable antigen-specific responses 14 months after vaccination in African infants
door: Odutola, A, et al.
Gepubliceerd in: (2012)

A new TB vaccine, MVA85A, induces durable antigen-specific responses 14 months after vaccination in African infants.
door: Odutola, A, et al.
Gepubliceerd in: (2012)

Two doses of candidate TB vaccine MVA85A in antiretroviral therapy (ART) naive subjects gives comparable immunogenicity to one dose in ART+ subjects
door: Dieye, T, et al.
Gepubliceerd in: (2013)

A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime - MVA85A boost in healthy UK adults
door: Wilkie, M, et al.
Gepubliceerd in: (2019)

Safety and immunogenicity of boosting BCG vaccinated subjects with BCG: comparison with boosting with a new TB vaccine, MVA85A.
door: Whelan, K, et al.
Gepubliceerd in: (2009)

Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults.
door: Pathan, A, et al.
Gepubliceerd in: (2012)

Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults
door: Pathan, A, et al.
Gepubliceerd in: (2012)

Differential cytokine levels in adults induced by a Novel candidate TB boost vaccine, MVA85A-according to previous BCG vaccination status
door: Owiafe, P, et al.
Gepubliceerd in: (2012)

Two doses of candidate TB vaccine MVA85A in antiretroviral therapy (ART) naïve subjects gives comparable immunogenicity to one dose in ART+ subjects.
door: Tandakha N Dieye, et al.
Gepubliceerd in: (2013-01-01)

Correction: Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85A.
door: Kathryn T. Whelan, et al.
Gepubliceerd in: (2011-01-01)

TB vaccine development: where are we and why is it so difficult?
door: Wilkie, M, et al.
Gepubliceerd in: (2014)

Correction: Two Doses of Candidate TB Vaccine MVA85A in Antiretroviral Therapy (ART) Naïve Subjects Gives Comparable Immunogenicity to One Dose in ART+ Subjects.
door: Tandakha N. Dieye, et al.
Gepubliceerd in: (2013-01-01)

A first-in-human phase 1 trial to evaluate the safety and immunogenicity of the candidate tuberculosis vaccine MVA85A-IMX313, administered to BCG-vaccinated adults.
door: Minhinnick, A, et al.
Gepubliceerd in: (2016)

Diagnosis of extrapulmonary TB: Experience with the Xpert MTB/Rif assay
door: C.N. Govind, et al.
Gepubliceerd in: (2014-04-01)

Evaluation of Xpert MTB/RIF assay for the diagnosis of paediatric TB
door: F. Ismail, et al.
Gepubliceerd in: (2014-04-01)

Correction: Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85A
Gepubliceerd in: (2011-01-01)

Diagnostic performance of GeneXpert MTB/RIF in detecting MTB in smear-negative presumptive TB patients
door: Raksha Rimal, et al.
Gepubliceerd in: (2022-04-01)

Impact of introduction of Xpert MTB/RIF test on tuberculosis (TB) diagnosis in a city with high TB incidence in Brazil.
door: Giovana Rodrigues Pereira, et al.
Gepubliceerd in: (2018-01-01)

Enhancing TB case detection: experience in offering upfront Xpert MTB/RIF testing to pediatric presumptive TB and DR TB cases for early rapid diagnosis of drug sensitive and drug resistant TB.
door: Neeraj Raizada, et al.
Gepubliceerd in: (2014-01-01)

Effects of MVA85A vaccine on tuberculosis challenge in animals: systematic review
door: Mcshane, H, et al.
Gepubliceerd in: (2016)

TB or not TB?
door: Andrew Pirotte, et al.
Gepubliceerd in: (2024-04-01)

Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial.
door: Satti, I, et al.
Gepubliceerd in: (2014)

Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: A phase 1, double-blind, randomised controlled trial
door: Satti, I, et al.
Gepubliceerd in: (2014)